PERTH, Australia – Australian regenerative medicine company Mesoblast Ltd.'s allogeneic cell therapy candidate, MPC-150-IM, failed to meet the primary endpoint in a phase IIb trial in end-stage heart failure patients implanted with a left ventricular assist device (LVAD), but it delivered meaningful clinical results that may make it approvable.